Debbie Rigby takes a look at the latest in research news
Aspirin, clopidogrel, or a combination of aspirin with dipyridamole are first-line options for secondary stroke prevention in the absence of atrial fibrillation. Dual antiplatelet therapy has a benefit in the first three weeks after stroke, but patients should change to a single antiplatelet drug after this time. Anticoagulants are indicated if the patient has atrial fibrillation. Combinations of anticoagulants and antiplatelet drugs should be avoided.
Aust Prescr 2021;44:85-90.
This cochrane review concluded that fast-acting beta₂‐agonist and inhaled corticosteroids (ICS) in the same device is clinically effective in adults and adolescents with mild asthma. When used as needed it is as effective as regular ICS and reduces asthma‐related hospital admissions or unscheduled healthcare visits, and average exposure to ICS, and is unlikely to be associated with an increase in adverse events.
Cochrane Database of Systematic Reviews 2021, Issue 5.
A systematic review and meta-analysis of 20 RCTs has concluded that triple therapy with ICS/LAMA/LABA compared with dual therapy (ICS/LABA) is significantly associated with fewer severe asthma exacerbations and modest improvements in asthma control but no significant difference in quality of life or most adverse effects.
JAMA. Published online May 19, 2021.
Atopic dermatitis is an inflammatory skin disorder affecting up to 20% of children and 10% of adults. Systemic therapy is required to control skin inflammation, reduce symptoms, prevent flares, and improve quality of life in children and adults with moderate to severe atopic dermatitis that does not respond to maximised topical therapies. Systemic immunomodulating agents include cyclosporine A, azathioprine, methotrexate, mycophenolate, and dupilumab.
J Asthma Allergy 2021;14:595-607.